Further evaluation of the efficacy of selpercatinib was done in an ongoing multicenter, open-label multi-cohort trial in 41 patients with RET fusion-positive tumors beyond NSCLC and thyroid cancers. The gene discussed is RET; the disease is thyroid gland carcinoma.